Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulations
The early stages of alpha cell dysregulation led to robust beta cell functional mass compensation driven by elevated fasting glucose. When the dysregulation progressed further, glucose levels rose to levels of glucotoxicity, exacerbating beta cell functional mass loss and accelerating the onset of type 2 diabetes. The various markers of diabetes (fasting glucose, 2 h plasma glucose and HbA<sub>1c</sub>) differed in terms of the prediction of timing of onset of disease, depending on the extent of alpha cell dysregulation.
Authors
- Tina Vilsbøll (ORCID: https://orcid.org/0000-0002-0456-6787)
- Arthur Sherman (ORCID: https://orcid.org/0000-0002-8372-5941)
- Jonatan I. Bagger (ORCID: https://orcid.org/0000-0003-3174-1613)
- Vijaya Subramanian (ORCID: https://orcid.org/0000-0001-8292-1759)
- Filip K. Knop (ORCID: https://orcid.org/0000-0002-2495-5034)
- Jens J Holst
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Johns Hopkins University (US)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk Foundation (DK)
- Gentofte Hospital (DK)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
Publication Details
- Journal
- Diabetologia
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1007/s00125-025-06524-1
- Citations
- 2
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases